“…Treatments using typical antipsychotics alone or in combination with psychotherapies, many of them evaluated in open trials and without placebo (PL) control, have usually failed (Dally, 1966;Vandereyken and Pierlot, 1982;Vandereyken, 1984;Ruggero et al, 2001;Cassano et al, 2003). More recently, atypical antipsychotics, olanzapine (OLA), risperidone and amisulpride, in particular, in either single cases or in small patient groups, had been shown to improve eating habits, weight and some psychopathological aspects of AN (depression, anxiety, obsessivity-compulsivity, psychoticism) (Hansen, 1999;Newman Tocker, 2000;Ridley-Siegert, 2000;La Via et al, 2000;Coates, 2000;Gaskill et al, 2001;Mehler et al, 2001;Ruggero et al, 2001;Leucht et al, 2002;Jensen and Mejihede, 2002;Powers et al, 2002;Carver et al, 2002;Ercan et al, 2003;Malina et al, 2003;Boachie et al, 2003;Pederson et al, 2003;Mangano et al, 2004;Barbarich et al, 2004;Mondraty et al, 2005;Attia et al, 2005;Hillebrand et al, 2005;Menaster, 2005;Bosanac et al, 2005). But as these therapies were administered in open trials without PL control, the significance of the positive results is questionable.…”